Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 381 | 27 | 351 |
| Samples | 208 | 24 | 182 |
| Peptides | 162 | 21 | 142 |
Function
IL3RA · Interleukin 3 receptor subunit alpha
The protein encoded by this gene is an interleukin 3 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL3 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL3. This gene and the gene encoding the colony stimulating factor 2 receptor alpha chain (CSF2RA) form a cytokine receptor gene cluster in a X-Y pseudoautosomal region on chromosomes X or Y. Alternatively spliced transcript variants encoding distinct isoforms have been found. [provided by RefSeq, Jun 2012].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 152 amino-acid changes on canonical ENST00000331035 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL3RA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL3RA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 2/42 5% | 19/612 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 16/1390 1% |
| Melanoma | 0/210 0% | 23/1899 1% |
| Colorectal Carcinoma | 1/143 1% | 34/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Gastric Carcinoma | 1/74 1% | 13/1809 1% |
| Neuroendocrine Tumour | 3/154 2% | 2/577 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Prostate Carcinoma | 1/13 8% | 5/2105 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Breast Carcinoma | 1/144 1% | 7/3264 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
Mutation Distribution
Where IL3RA is mutated · all tissues, split by cell line vs tissue
How many mutations in IL3RA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 381 mutations in IL3RA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|